Angiotensin and ANP secretion during chronically controlled increments in atrial pressure.
The primary objective of this study was to determine whether angiotensin II (ANG II) has direct effects on the atrium to chronically stimulate the secretion of atrial natriuretic peptide (ANP) by actions that are independent of its vasoconstrictor and fluid-retaining effects that increase ANP secretion indirectly by raising atrial pressure. In five dogs, right atrial pressure (RAP) was controlled at approximately 5.5 mmHg above control levels for 8 days by employing an externally adjustable occluder around the pulmonary artery and a servo-control system, and plasma levels of ANG II were fixed at either normal (days 1-3 and 7-8) or high (days 4-6) physiological concentrations by chronic infusion of captopril+ANG II. When plasma ANG II was maintained at normal levels during servo-control of RAP, plasma ANP concentration increased five- to sixfold and sodium balance was achieved at a reduced arterial pressure (-14 mmHg). In contrast, despite increased plasma levels of ANP, the high rate of ANG II infusion produced marked sodium retention during the initial 24 h; however, the antinatriuresis was not sustained because the servo-control system partially deflated the pulmonary artery occluder to prevent fluid-induced increments in RAP. Moreover, in the absence of a change in RAP, high plasma levels of ANG II did not influence plasma ANP concentration. These findings indicate that the plasma levels of ANP achieved in heart failure increase renal excretory capability and allow fluid balance to be achieved at a substantial fall in mean arterial pressure as long as there is minimal involvement of the renin-angiotensin system.(ABSTRACT TRUNCATED AT 250 WORDS)
Lohmeier
T E
TE
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216-4505.
Shin
Y
Y
Reinhart
G A
GA
Hester
R L
RL
D000804:Angiotensin II / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D016280:Atrial Function, Right; D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D002216:Captopril / Q000494:pharmacology; D004285:Dogs; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D009994:Osmolar Concentration; D011312:Pressure; D013997:Time Factors
D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D002216:Captopril